Mucosal immunity induced by enhance-potency inactivated and oral polio vaccines
- PMID: 1845806
- DOI: 10.1093/infdis/163.1.1
Mucosal immunity induced by enhance-potency inactivated and oral polio vaccines
Abstract
Oral polio vaccine (OPV) is recommended for routine immunization in the United States in part because of its ability to induce intestinal and pharyngeal immunity to reinfection. Mucosal immunity produced by OPV and enhanced-potency inactivated polio vaccine (E-IPV) was compared by challenging vaccines with type 1 OPV. Fewer OPV (25%) than E-IPV (63%) vaccinees excreted OPV virus in stool after challenge. The mean stool virus titer was higher and the duration of shedding longer among E-IPV excreters. Only one E-IPV and three OPV vaccinees shed virus in the pharynx after challenge. Prechallenge serum neutralizing antibody levels were not statistically different among E-IPV vaccinees who did and did not shed virus; these levels were much higher than those of OPV vaccinees. Poliovirus-specific IgA levels in stool did not correlate with viral excretion. E-IPV was less effective than OPV in preventing and limiting intestinal infection, even though it induced higher postvaccination serum antibody levels.
Similar articles
-
Intestinal Immune Responses to Type 2 Oral Polio Vaccine (OPV) Challenge in Infants Previously Immunized With Bivalent OPV and Either High-Dose or Standard Inactivated Polio Vaccine.J Infect Dis. 2018 Jan 17;217(3):371-380. doi: 10.1093/infdis/jix556. J Infect Dis. 2018. PMID: 29304199 Free PMC article. Clinical Trial.
-
Comparative evaluation of immunization with live attenuated and inactivated poliovirus vaccines.Ann N Y Acad Sci. 1995 May 31;754:97-107. doi: 10.1111/j.1749-6632.1995.tb44442.x. Ann N Y Acad Sci. 1995. PMID: 7625685
-
Exploring the relationship between polio type 2 serum neutralizing antibodies and intestinal immunity using data from two randomized controlled trials of new bOPV-IPV immunization schedules.Vaccine. 2017 Dec 19;35(52):7283-7291. doi: 10.1016/j.vaccine.2017.11.006. Epub 2017 Nov 14. Vaccine. 2017. PMID: 29150209 Free PMC article. Clinical Trial.
-
Systematic review of mucosal immunity induced by oral and inactivated poliovirus vaccines against virus shedding following oral poliovirus challenge.PLoS Pathog. 2012;8(4):e1002599. doi: 10.1371/journal.ppat.1002599. Epub 2012 Apr 19. PLoS Pathog. 2012. PMID: 22532797 Free PMC article. Review.
-
Global eradication of poliomyelitis: reinvent the wheel or use existing options effectively?Public Health Rev. 1993-1994;21(1-2):143-50. Public Health Rev. 1993. PMID: 8041881 Review.
Cited by
-
Inactivated Poliovirus Vaccine: Recent Developments and the Tortuous Path to Global Acceptance.Pathogens. 2024 Mar 4;13(3):224. doi: 10.3390/pathogens13030224. Pathogens. 2024. PMID: 38535567 Free PMC article. Review.
-
Population Immunity and Polio Eradication.Pathogens. 2024 Feb 20;13(3):183. doi: 10.3390/pathogens13030183. Pathogens. 2024. PMID: 38535527 Free PMC article. Review.
-
Four statistical frameworks for assessing an immune correlate of protection (surrogate endpoint) from a randomized, controlled, vaccine efficacy trial.Vaccine. 2024 Apr 2;42(9):2181-2190. doi: 10.1016/j.vaccine.2024.02.071. Epub 2024 Mar 8. Vaccine. 2024. PMID: 38458870 Review.
-
Quantitative Analysis of the Instant and Persistent Inhibition Effects of Maternal Poliovirus Antibodies on the Immune Response in a Phase IV Trial of a Sabin Strain-Based Inactivated Poliovirus Vaccine.Vaccines (Basel). 2024 Feb 19;12(2):217. doi: 10.3390/vaccines12020217. Vaccines (Basel). 2024. PMID: 38400200 Free PMC article.
-
Use of Inactivated Polio Vaccine Among U.S. Adults: Updated Recommendations of the Advisory Committee on Immunization Practices - United States, 2023.MMWR Morb Mortal Wkly Rep. 2023 Dec 8;72(49):1327-1330. doi: 10.15585/mmwr.mm7249a3. MMWR Morb Mortal Wkly Rep. 2023. PMID: 38060431 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
